Recombinant human immunodeficiency Pr55(gag) virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies

Virology

Volumn 235, Issue 1, 1997, Pages 26-39

  Deml, Ludwig ^a   Schirmbeck, Reinhold ^b   Reimann, Jörg ^b   Wolf, Hans ^a   Wagner, Ralf ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; NEUTRALIZING ANTIBODY; VIRUS PROTEIN; VIRUS VACCINE;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CHIMERA; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; PRIORITY JOURNAL; VIRUS PARTICLE;

HUMAN HERPESVIRUS 4; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030796280     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8668     Document Type: Article

References (75)

1. Abimiku A. G., Franchini G., Aldrich K., Myagkikh M., Markham P., Gard E., Gallo R. C., Robert Guroff M. Humoral and cellular immune responses in rhesus macaques infected with human immunodeficiency virus type 2. AIDS Res. Hum. Retroviruses. 11:1995;383-393.
2. Ariyoshi K., Harwood E., Chiengsong Popov R., Weber J. Is clearance of HIV-1 viraemia at seroconversion mediated by neutralising antibodies? Lancet. 340:1992;1257-1258.
3. Ariyoshi K., Cham F., Berry N., Jaffar S., Sabally S., Corrah T., Whittle H. HIV-2-specific cytotoxic T-lymphocyte activity is inversely related to proviral load. AIDS. 9:1995;555-559.
4. Berman P. W., Gregory T. J., Riddle L., Nakamura G. R., Champe M. A., Porter J. P., Wurm F. M., Hershberg R. D., Cobb E. K., Eichberg J. W. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature. 345:1990;622-625.
5. Bevan M. J. Antigen recognition. Class discrimination in the world of immunology. Nature. 325:1987;192-194.
6. Borrow P., Lewicki H., Hahn B. H., Shaw G. M., Oldstone M. B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:1994;6103-6110.
7. Bryson Y. J., Pang S., Wei L. S., Dickover R., Diagne A., Chen I. S. Clearance of HIV infection in a perinatally infected infant. N. Engl. J. Med. 332:1995;833-838.
8. Byrne J. A., Oldstone M. B. Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus. VI. Migration and activity in vivo in acute and persistent infection. J. Immunol. 136:1986;698-704.
9. Cabral G. A., Marciano Cabral F., Funk G. A., Sanchez Y., Hollinger F. B., Melnick J. L., Dreesman G. R. Cellular and humoral immunity in guinea pigs to two major polypeptides derived from hepatitis B surface antigen. J. Gen. Virol. 38:1978;339-350.
10. Cao Y., Qin L., Zhang L., Safrit J., Ho D. D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332:1995;201-208.
11. Cheingsong Popov R., Panagiotidi C., Bowcock S., Aronstam A., Wadsworth J., Weber J. Relation between humoral responses to HIV Gag and Env proteins at seroconversion and clinical outcome of HIV infection. Br. Med. J. 302:1991;23-26.
12. Cheynier R., Langlade Demoyen P., Marescot M. R., Blanche S., Blondin G., Wain Hobson S., Griscelli C., Vilmer E., Plata F. Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers. Eur. J. Immunol. 22:1992;2211-2217.
13. Clementi M., Bagnarelli P., Menzo S., Valenza A., Manzin A., Varaldo P. E. Clearance of HIV-1 viraemia after seroconversion. Lancet. 341:1993;315-316.
14. Cox W. I., Tartaglia J., Paoletti E. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology. 195:1993;845-850.
15. De Maria A., Cirillo C., Moretta L. Occurrence of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T cell activity in apparently uninfected children born to HIV-1-infected mothers. J. Infect. Dis. 170:1994;1296-1299.
16. gag. Virology. 235:1997;10-25.
17. Fouts T. R., Binley J. M., Trkola A., Robinson J. E., Moore J. P. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 71:1997;2779-2785.
18. Fultz P. N., Nara P., Barre Sinoussi F., Chaput A., Greenberg M. L., Muchmore E., Kieny M. P., Girard M. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science. 256:1992;1687-1690.
19. Girard M., Kieny M. P., Pinter A., Barre Sinoussi F., Nara P., Kolbe H., Kusumi K., Chaput A., Reinhart T., Muchmore E. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl. Acad. Sci. U. S. A. 88:1991;542-546.
20. Griffiths J. C., Berrie E. L., Holdsworth L. N., Moore J. P., Harris S. J., Senior J. M., Kingsman S. M., Kingsman A. J., Adams S. E. Induction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty viruslike particles in a clinically relevant adjuvant. J. Virol. 65:1991;450-456.
21. Griffiths J. C., Harris S. J., Layton G. T., Berrie E. L., French T. J., Burns N. R., Adams S. E., Kingsman A. J. Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: Induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion. J. Virol. 67:1993;3191-3198.
22. Haffar O. K., Smithgall M. D., Moran P. A., Travis B. M., Zarling J. M., Hu S. L. HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like Gag-Env particles. Virology. 183:1991;487-495.
23. Haffar O. K., Moran P. A., Smithgall M. D., Diegel M. L., Sridhar P., Ledbetter J. A., Zarling J. M., Hu S. L. Inhibition of virus production in peripheral blood mononuclear cells from human immunodeficiency virus (HIV) type 1-seropositive donors by treatment with recombinant HIV-like particles. J. Virol. 66:1992;4279-4287.
24. Harris S. J., Gearing A. J., Layton G. T., Adams S. E., Kingsman A. J. Enhanced proliferative cellular responses to HIV-1 V3 peptide and gp120 following immunization with V3:Ty virus-like particles. Immunology. 77:1992;315-321.
25. Heeg K., Kuon W., Wagner H. Vaccination of class I major histocompatibility complex (MHC)-restricted murine CD8+ cytotoxic T lymphocytes towards soluble antigens: Immunostimulating-ovalbumin complexes enter the class I MHC-restricted antigen pathway and allow sensitization against the immunodominant peptide. Eur. J. Immunol. 21:1991;1523-1527.
26. Ho D. D., Sarngadharan M. G., Hirsch M. S., Schooley R. T., Rota T. R., Kennedy R. C., Chanh T. C., Sato V. L. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J. Virol. 61:1987;2024-2028.
27. Huang Y., Zhang L., Ho D. D. Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection. J. Virol. 69:1995;93-100.
28. Johnson R. P., Trocha A., Yang L., Mazzara G. P., Panicali D. L., Buchanan T. M., Walker B. D. HIV-1 Gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the Gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J. Immunol. 147:1991;1512-1521.
29. Kast W. M., Brandt R. M., Melief C. J. Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination. Eur. J. Immunol. 23:1993;1189-1192.
30. Koup R. A., Ho D. D. Shutting down HIV. Nature. 370:1994;416.
31. Koup R. A., Safrit J. T., Cao Y., Andrews C. A., McLeod G., Borkowsky W., Farthing C., Ho D. D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:1994;4650-4655.
32. Kutubuddin M., Simons J., Chow M. Poliovirus-specific major histocompatibility complex class I-restricted cytolytic T-cell epitopes in mice localize to neutralizing antigenic regions. J. Virol. 66:1992;5967-5974.
33. Langlade Demoyen P., Ngo Giang Huong N., Ferchal F., Oksenhendler E. Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients. J. Clin. Invest. 93:1994;1293-1297.
34. Layton G. T., Harris S. J., Gearing A. J., Hill Perkins M., Cole J. S., Griffiths J. C., Burns N. R., Kingsman A. J., Adams S. E. Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles. J. Immunol. 151:1993;1097-1107.
35. Lopes L. M., Chain B. M. Liposome-mediated delivery stimulates a class I-restricted cytotoxic T cell response to soluble antigen. Eur. J. Immunol. 22:1992;287-290.
36. Lu S., Santoro J. C., Fuller D. H., Haynes J. R., Robinson H. L. Use of DNAs expressing HIV-1 env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology. 209:1995;147-154.
37. Luo L., Li Y., Cannon P. M., Kim S., Kang C. Y. Chimeric Gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies. Proc. Natl. Acad. Sci. USA. 89:1992;10527-10531.
38. Macilwain C. US puts large-scale AIDS vaccine trials on ice as 'premature'. Nature. 369:1994;593.
39. Mannhalter J. W., Fischer M. B., Wolf H. M., Kupcu Z., Barrett N., Dorner F., Eder G., Eibl M. M. Immunization of chimpanzees with recombinant gp160, but not infection with human immunodeficiency virus type 1, induces envelope-specific Th1 memory cells. J. Infect. Dis. 171:1995;437-440.
40. Martinez-Kinader B., Lipford G. B., Wagner H., Heeg K. Sensitization of MHC class I-restricted T cells to exogenous proteins: Evidence for an alternative class I-restricted antigen presentation pathway. Immunology. 86:1995;287-295.
41. Martinon F., Gras Masse H., Boutillon C., Chirat F., Deprez B., Guillet J. G., Gomard E., Tartar A., Levy J. P. Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein. J. Immunol. 149:1992;3416-3422.
42. Michel M. L., Mancini M., Riviere Y., Dormont D., Tiollais P. T- and B-lymphocyte responses to human immunodeficiency virus (HIV) type 1 in macaques immunized with hybrid HIV/hepatitis B surface antigen particles. J. Virol. 64:1990;2452-2455.
43. Modrow S., Hoflacher B., Mertz R., Wolf H. Carrier-bound synthetic peptides. Use as antigen in HIV-1 ELISA tests and in antiserum production. J. Immunol. Methods. 118:1989;1-7.
44. Nair S., Zhou X., Huang L., Rouse B. T. Class I restricted CTL recognition of a soluble protein delivered by liposomes containing lipophilic polylysines. J. Immunol. Methods. 152:1992;237-243.
45. Newman M. J., Wu J. Y., Gardner B. H., Munroe K. J., Leombruno D., Recchia J., Kensil C. R., Coughlin R. T. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. J. Immunol. 148:1992;2357-2362.
46. Osterrieder N., Wagner R., Brandmuller C., Schmidt P., Wolf H., Kaaden O. R. Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB). Virology. 208:1995;500-510.
47. Pinto L. A., Sullivan J., Berzofsky J. A., Clerici M., Kessler H. A., Landay A. L., Shearer G. M. Env-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J. Clin. Invest. 96:1995;867-876.
48. Plata F., Autran B., Martins L. P., Wain Hobson S., Raphael M., Mayaud C., Denis M., Guillon J. M., Debre P. AIDS virus-specific cytotoxic T lymphocytes in lung disorders. Nature. 328:1987;348-351.
49. Quinnan G. V. Jr., Kirmani N., Rook A. H., Manischewitz J. F., Jackson L., Moreschi G., Santos G. W., Saral R., Burns W. H. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N. Engl. J. Med. 307:1982;7-13.
50. Reddy R., Zhou F., Nair S., Huang L., Rouse B. T. In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. J. Immunol. 148:1992;1585-1589.
51. Reimann J., Bellan A., Conradt P. Development of autoreactive L3T4+ T cells from double-negative (L3T4-/Ly-2-) Thy-1+ spleen cells of normal mice. Eur. J. Immunol. 18:1988;989-999.
52. Roben P., Moore J. P., Thali M., Sodroski J., Barbas C. F. I., Burton D. R. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68:1994;4821-4828.
53. Rowland-Jones S., Sutton J., Arijoshi K., Dong T., Gotch F., Mo-Adam S., Whitby D., Sabally S., Allimore A., Corrah T., Taciguchi M., Schultz T., McMichal A., Whittle H. HIV-specific cytotoxic T-cells in HIV exposed but uninfected Gambian woman. Nature Med. 1:1995;59-64.
54. Ruegg C. L., Monell C. R., Strand M. Inhibition of lymphoproliferation by a synthetic peptide with sequence identity to gp41 of human immunodeficiency virus type 1. J. Virol. 63:1989;3257-3260.
55. Ruegg C. L., Strand M. A synthetic peptide with sequence identity to the transmembrane protein gp41 of HIV-1 inhibits distinct lymphocyte activation pathways dependent on protein kinase C and intracellular calcium influx. Cell Immunol. 137:1991;1-13.
56. Safrit J. T., Andrews C. A., Zhu T., Ho D. D., Koup R. A. Characterization of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: Recognition of autologous virus sequences within a conserved immunodominant epitope. J. Exp. Med. 179:1994;463-472.
57. Sattentau Q. J., Moore J. P. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182:1995;185-196.
58. Schild H., Norda M., Deres K., Falk K., Rotzschke O., Wiesmuller K. H., Jung G., Rammensee H. G. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide. J. Exp. Med. 174:1991;1665-1668.
59. Schirmbeck R., Deml L., Melber K., Wolf H., Wagner R., Reimann J. Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens. Vaccine. 13:1995a;857-865.
60. Schirmbeck R., Melber K., Mertens T., Reimann J. Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: Implication for the pathogenesis of HBV-induced hepatitis. J. Virol. 68:1994;1418-1425.
61. Schirmbeck R., Melber K., Reimann J. Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for major histocompatibility complex class I-restricted epitope presentation. Eur. J. Immunol. 25:1995b;1063-1070.
62. Sethi K. K., Omata Y., Schneweis K. E. Protection of mice from fatal herpes simplex virus type 1 infection by adoptive transfer of cloned virus-specific and H-2-restricted cytotoxic T lymphocytes. J. Gen. Virol. 64:1983;443-447.
63. Takahashi H., Cohen J., Hosmalin A., Cease K. B., Houghten R., Cornette J. L., DeLisi C., Moss B., Germain R. N., Berzofsky J. A. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA. 85:1988;3105-3109.
64. Wagner R., Fliessbach H., Wanner G., Motz M., Niedrig M., Deby G., von Brunn A., Wolf H. Studies on processing, particle formation, and immunogenicity of the HIV-1gag. Arch. Virol. 127:1992;117-137.
65. gag. J. Gen. Virol. 74:1993;1261-1269.
66. gag. Virology. 200:1994a;162-175.
67. Wagner R., Deml L., Wolf H. Polyvalent, recombinant HIV-1 virus-like particles: Novel HIV-1 vaccine strategies. Antibiot. Chemother. 46:1994b;48-61.
68. Wagner R., Deml L., Fitzon T., Wolf H. Vaccines 95: Molecular Approaches to the Control of Infectious Diseases. 1995;Cold Spring Harbor Laboratory Press, Cold Spring Harbor. p. 347-356.
69. Wagner R., Deml L., Schirmbeck R., Niedrig M., Reimann J., Wolf H. Construction, expression and immunogenicity of chimeric HIV-1 virus-like particles. Virology. 220:1996;128-140.
70. Walker B. D., Chakrabarti S., Moss B., Paradis T. J., Flynn T., Durno A. G., Blumberg R. S., Kaplan J. C., Hirsch M. S., Schooley R. T. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature. 328:1987;345-348.
71. Weber J. N., Clapham P. R., Weiss R. A., Parker D., Roberts C., Duncan J., Weller I., Carne C., Tedder R. S., Pinching A. J. Human immunodeficiency virus infection in two cohorts of homosexual men: Neutralising sera and association of anti-Gag antibody with prognosis. Lancet. 1:1987;119-122.
72. Weiss R. A., Clapham P. R., Cheingsong Popov R., Dalgleish A. G., Carne C. A., Weller I. V., Tedder R. S. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature. 316:1985;69-72.
73. Weiss R. A., Clapham P. R., Weber J. N., Dalgleish A. G., Lasky L. A., Berman P. W. Variable and conserved neutralization antigens of human immunodeficiency virus. Nature. 324:1986;572-575.
74. Wolf H., Modrow S., Wagner R. Odile R. Retroviruses of Human AIDS and Related Animal Diseases. 1994;299-307 Marnes-La-CoquetteColloque Des Cent Gardes, Paris.
75. Yamada M., Zurbriggen A., Oldstone M. B., Fujinami R. S. Common immunologic determinant between human immunodeficiency virus type 1 gp41 and astrocytes. J. Virol. 65:1991;1370-1376.